On April 29, 2021 Zelluna Immunotherapy AS reported an exclusive research collaboration with Etcembly Ltd to discover T cell receptors immune pattern recognition system EMLy (Press release, Etcembly, APR 29, 2021, View Source [SID1234612570]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Zelluna Immunotherapy, the company pioneering allogeneic "off the shelf" TCR based natural killer (TCR-NK) cells for the treatment of cancer, and Etcembly, a start-up developing innovative machine learning techniques in immune pattern recognition for in silico discovery of novel TCR specificities, today announce an exclusive collaboration to discover TCRs with an initial focus on a widely expressed and well-validated solid cancer antigen.

TCR-NK products are a novel class of allogeneic cellular therapies that combine the inherent killing mechanism, efficiency, and the allogeneic nature of NK cells with the targeting capabilities of TCRs. TCR engineered NK cells may unlock the potential to treat a wide range of currently untreatable cancers.

Luise Weigand, Head of Research at Zelluna said…

"I am delighted that we have the opportunity to combine our proprietary TCR-NK platform with the high potential of Etcembly’s innovative approach to TCR discovery through the application of artificial intelligence. We are looking forward to working with the Etcembly team on breaking new ground in the discovery of highly potent TCRs for cancer immunotherapy. This collaboration forms part of our wider strategy for discovering TCRs which includes in-licensing and our own recently initiated discovery efforts."
Dr Michelle Teng, Founder CEO of Etcembly continues…

"We relish this unprecedented opportunity to work with Zelluna at such an early stage of our company – a testament to the confidence in our immune prediction platform EMLy. This is the start of an exciting collaboration in pursuit of defining a new paradigm of learn drug discovery for immunotherapy."